BiotechTube

Enfortumab Vedotin

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adenoid Cystic Carcinoma

Conditions

Adenoid Cystic Carcinoma

Trial Timeline

Mar 31, 2025 → Mar 1, 2027

NCT ID
NCT06891560

About Enfortumab Vedotin

Enfortumab Vedotin is a phase 2 stage product being developed by Astellas Pharma for Adenoid Cystic Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06891560. Target conditions include Adenoid Cystic Carcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (14)

NCT IDPhaseStatus
NCT07139977Phase 2Recruiting
NCT07347314Phase 2Recruiting
NCT06862219ApprovedRecruiting
NCT06891560Phase 2Recruiting
NCT06553885Phase 2Recruiting
NCT06394570Phase 1/2Recruiting
NCT06011954Pre-clinicalRecruiting
NCT05868265Phase 2Recruiting
NCT04754191Phase 2Active
NCT05014139Phase 1Terminated
NCT04995419Phase 2Completed
NCT03219333Phase 2Completed
NCT03070990Phase 1Completed
NCT02091999Phase 1Completed

Competing Products

11 competing products in Adenoid Cystic Carcinoma

See all competitors
ProductCompanyStageHype Score
LenvatinibEisaiPhase 2
52
Lenvatinib + PembrolizumabEisaiPhase 2
52
P-SamAstraZenecaPhase 2
52
CetuximabMerckPhase 1/2
41
PembrolizumabMerckPhase 2
52
DovitinibNovartisPhase 2
52
Dovitinib (TKI258)NovartisPhase 2
52
AG-013736 (AXITINIB)PfizerPhase 2
51
RegorafenibBayerPhase 2
49
Mometasone Furoate nasal spray + PlaceboOrganonPhase 3
72
mometasone furoate nasal sprayOrganonApproved
80

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85